Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 16,667 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $6.25, for a total transaction of $104,168.75. Following the completion of the transaction, the insider directly owned 1,226,507 shares of the company’s stock, valued at $7,665,668.75. This trade represents a 1.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Beth Hecht also recently made the following trade(s):

• On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.45, for a total value of $124,169.15.
• On Friday, January 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.43, for a total value of $123,835.81.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock traded up $0.13 on Wednesday, hitting $6.07. The company had a trading volume of 2,355,176 shares, compared to its average volume of 2,095,509. The stock has a 50-day moving average of $7.18 and a 200-day moving average of $7.62. The firm has a market capitalization of $1.01 billion, a P/E ratio of -606.39 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a twelve month low of $3.65 and a twelve month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million. Xeris Biopharma had a negative return on equity of 3.01% and a net margin of 0.19%. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Institutional Investors Weigh In On Xeris Biopharma

A number of large investors have recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new stake in shares of Xeris Biopharma during the 4th quarter worth approximately $25,000. AlphaQuest LLC bought a new position in Xeris Biopharma in the third quarter valued at about $35,000. Caitong International Asset Management Co. Ltd raised its stake in Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after acquiring an additional 7,421 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after purchasing an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in shares of Xeris Biopharma by 179.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after buying an additional 5,000 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 results beat on EPS and management set aggressive revenue goals — Xeris reported Q4 EPS of about $0.06 (vs. ~$0.03 consensus) and highlighted record revenue growth plus a target of over 30% revenue growth for 2026 while increasing investment in Recorlev and advancing XP‑8121, which supports the recent upside in the stock. Xeris targets over 30% revenue growth in 2026 while expanding Recorlev investment and advancing XP-8121
• Positive Sentiment: Analyst support: HC Wainwright maintains a Buy and $10 price target and published multi‑year EPS runway (FY2026–FY2030 forecasts showing progressive profit improvement), which reinforces investor confidence in upside to the current share price. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright
• Positive Sentiment: Bull case commentary: A recent Seeking Alpha piece argues Xeris is undervalued given its drug portfolio and development pipeline, which can attract value‑oriented and biotech growth investors. Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
• Neutral Sentiment: Earnings call and transcripts are available for detail — investors can review management’s commentary on margin progress, Recorlev commercialization plans and pipeline timing in the Q4 2025 call transcript. Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
• Neutral Sentiment: Market reaction coverage: Several outlets note the stock rallied following the quarter and guidance, reflecting short‑term trader interest on the beat and outlook. Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance
• Negative Sentiment: Recorlev patent disputes pose downside risk — coverage highlights active patent battles around Recorlev that could create legal uncertainty, potential injunction or royalty impacts that would weigh on valuation if outcomes are adverse. Xeris Biopharma Balances New Profitability With Recorlev Patent Battles
• Negative Sentiment: Analyst estimate trims for near‑to‑midterm years — HC Wainwright’s note included small reductions to FY2026–FY2029 EPS forecasts (while keeping a Buy), signaling expected slower near‑term margin progression and tempering upside in the near term. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on XERS. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a report on Monday. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Piper Sandler boosted their price target on Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Finally, Barclays began coverage on Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 target price for the company. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Xeris Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $10.08.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.